Acute Kidney Injury

Every cause of AKI lives in one of three places, and the whole workup is built around finding which. Pre-renal problems sit before the kidney: anything that reduces renal blood flow — hypovolemia, hypotension from low cardiac output, systemic vasodilation, renal vasoconstriction — starves the glomeruli of the perfusion pressure filtration depends on. The nephrons themselves are initially intact; they are simply not being fed. Intrinsic (intrarenal) problems are direct damage to the renal tissue itself — acute tubular necrosis, acute interstitial nephritis, glomerulonephritis, intratubular obstruction — impairing nephron function from the inside. Post-renal problems sit after the kidney: a mechanical obstruction to urinary outflow — calculi, tumors, blood clots, neurogenic bladder, urethral obstruction, prostate enlargement — that refluxes urine back toward the renal pelvis.

The distribution matters clinically: in hospitalized patients, ATN accounts for about 45% of AKI and pre-renal disease about 21% — together roughly three-quarters of all cases — with obstruction around 10%, AKI on top of pre-existing CKD 13%, and glomerulonephritis, interstitial nephritis, and atheroemboli making up the rest. So when urine output falls, the two questions that solve most cases are “is this kidney being perfused?” and “is the urine getting out?”

Renal perfusion and GFR move together, and the kidney fights hard to protect both. When blood pressure or cardiac output falls, the afferent arteriole (inflow) compensates to maintain perfusion — and holds the line until systolic pressure drops below about 80 mm Hg. Meanwhile angiotensin II constricts the efferent arteriole (outflow), keeping pressure inside the glomerulus high enough to filter even when cardiac output is mildly to moderately reduced. This elegant two-valve system is exactly what common medications sabotage. ACE inhibitors and ARBs block the angiotensin II tone on the efferent arteriole — harmless in a well-perfused patient, but in hypoperfusion (and classically in bilateral renal artery stenosis or a solitary functioning kidney) they disable the compensation and worsen pre-renal failure. NSAIDs sit on the same nephrotoxin list, alongside aminoglycosides, vancomycin, amphotericin B, and iodinated contrast.

The causes of pre-renal AKI read like a hypoperfusion checklist: intravascular volume depletion, hypotension, sepsis, shock, over-diuresis, heart failure, and cirrhosis. The corollary is the most hopeful fact on this page: because the nephrons are starved rather than destroyed, pre-renal AKI reverses with prompt volume restoration — an isotonic fluid challenge is both therapeutic and diagnostic, and most pre-renal AKI recovers completely when treated early.

Acute tubular necrosis is ischemic and nephrotoxic injury to the tubular epithelium — most often ischemic, sometimes nephrotoxic or mixed — and the proximal tubules take the main hit. Dying tubular cells slough into the urine and form the classic muddy brown granular casts, the sediment finding that says ATN. A critical trap: serum creatinine lags behind the actual tubular injury — in early ATN the creatinine rise trails the real GFR drop, so a “normal” creatinine early does not exclude injury. The nephrotoxins that cause ATN are the same names to screen for on every medication list: vancomycin, aminoglycosides, amphotericin B, radiocontrast, NSAIDs, cisplatin, and the calcineurin inhibitors.

Post-renal injury is a plumbing problem that becomes a tissue problem. Obstruction — most often benign prostatic hyperplasia in men, plus ureteral calculi, malignancy, neurogenic bladder, blood clots after instrumentation, and urethral strictures — refluxes urine back into the kidney. Hydronephrosis develops, back-pressure extends into the collecting system, and distension plus rising intratubular pressure produce local ischemia. Left long enough, this becomes tubulointerstitial fibrosis and irreversible nephron loss — which is why early identification and prompt decompression are critical, and why a bladder scan belongs early in every falling-urine-output workup.

AKI unfolds in phases. The prodromal phase has normal urine output and varies in duration depending on the cause. The oliguric phase follows, with urine output typically between 50 and 500 mL/day and an unpredictable duration — and this is where patients die, because a kidney that cannot excrete water or potassium turns intake into volume overload (pulmonary edema, peripheral edema) and serum potassium into hyperkalemia. Both dangers cluster specifically in the oliguric phase, and so do the indications for dialysis. In the postoliguric phase, urine output gradually returns to normal — but serum creatinine and urea may not fall for several more days, so improving urine output alone does not mean the kidney has recovered. ATN can take weeks to months for complete recovery.

One high-output danger deserves its own name: post-obstructive diuresis, seen after relieving a urinary obstruction (a distinct entity, not a routine AKI phase). Prolonged urine production of 200 mL or more for at least 2 consecutive hours after the retention is relieved — or more than 3,000 mL in 24 hours — can strip the patient of sodium, potassium, magnesium, and volume fast enough to cause hypovolemic shock. And AKI leaves a scar even when it seems to resolve: at least 12–15% of AKI patients eventually need permanent dialysis, and repeated AKI cumulatively worsens renal function.